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1 
Abstract 
 Several aldehydes (butanal, pentanal, hexanal, 4-hydroxybenzaldehyde) were reacted with 
1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide (1) to produce novel C
2
 substituted 
imidazolium salts for the potential use against non-small cell lung cancer in humans. Compounds 
2-(1-hydroxypentyl)-1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide (3) and 2-(1-
hydroxyhexyl)-1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide (5) were successfully 
synthesized with structures supported by NMR and mass spectrometry. Characterization by 
1
H 
NMR showed evidence of 1 in both compounds. The tumor cell growth inhibition of 3 against 
non-small cell lung cancer lines NCI-A549, NCI-H460, HCC827, and NCI-H1975 was tested 
and found to be comparable to cisplatin as measured by MTT assay. Compounds were compared 
by their IC50 values against a panel of human cancer cell lines. The IC50 values for 3 were: 9 M 
for A549 cells, 7M for H460 cells, 5 M forHCC827 cells, and 3 M for H1975 cells. Cisplatin 
had IC50 values in the range of 3-8 M for these cell types, indicating that our compound had 
similar efficiency to a current chemotherapeutic agent. Similar IC50 values for 1 in the literature 
suggest C
2
 substituents may not significantly affect tumor cell growth inhibition.
1
 This may 
allow for different functional groups to be substituted at the C
2
 position in order to optimize 
properties such as water solubility and toxicity while not hindering therapeutic benefits.  
  
2 
Introduction 
     Developing new chemotherapeutic agents is of utmost importance as cancer continues to pose 
a great threat to human health. In the United States alone, it is predicted that 158,040 people will 
die from lung cancer in 2015 amounting to 27 % of total cancer-related deaths.
2
 Non-small cell 
lung cancer (NSCLC) accounts for 83 % of lung cancer diagnoses with early treatment being a 
combination of surgery and chemotherapy.
2
 A very low five-year survival rate of 17 %, even 
with continued chemotherapy, has prompted the investigation for novel chemotherapeutics.
2
 The 
goal of synthesizing new anti-tumor agents is to produce compounds with equivalent activity and 
better side effect profiles than currently available drugs. Cisplatin (Fig. 1) has been used in the 
treatment of many types of cancer including head and neck, testicular, and NSCLC but with 
numerous side effects.
3
 Cisplatin works by forming an intrastrand crosslink adduct with DNA 
resulting in tumor cell death (Fig. 1).
4
 A common problem when using cisplatin alone is that 
tumor cells can rapidly develop resistance, decreasing its effectiveness.
5
 To circumvent this 
problem, new treatment guidelines and drugs have been developed and used in combination with 
cisplatin. Combination therapy with inorganic cisplatin and additional drugs such as the natural 
product derivative, vinorelbine or the biologic, bevacizumab, helps to prevent resistance while 
maintaining therapeutic efficacy.
6
 
 
Fig. 1: Structure of cisplatin and representation of intrastrand DNA crosslink formation. 
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 Imidazolium salts (Fig. 2) have recently been investigated for their activity against cancer 
cells by using MTT assays.
1,7,8
 An MTT assay is a procedure that enables the viability of cells to 
be determined spectrophotometrically when a tetrazolium salt dye (MTT) is added. A 
measurable absorbance shift from the maximum (540 nm, DMSO) occurs when viable cells 
reduce the MTT compound to its colored formazan form.
9
 The ability for certain compounds to 
decrease cell viability can be compared using an IC50 value; the concentration at which 50 % cell 
growth occurs relative to control cells. Several Ag(I) N-heterocyclic carbene complexes derived 
from imidazolium salts were synthesized and found to inhibit tumor cell growth to a comparable 
level with cisplatin.
10
 These results prompted investigation into the anti-tumor activity of the 
imidazolium salts without the silver complex such as derivatives of 4,5-dichloro-1,3-
bis(naphthalen-2-ylmethyl)-imidazolium bromide (IC23).
1
 A derivative of IC23, compound 1 
(IC23H, Scheme 1), served as the template for the synthesis of numerous compounds with 
substitutions made at the C
2
 position. It was found that optimal tumor cell growth inhibition 
occurred when the imidazolium salts maintained both 1,3-bisnaphthylmethyl groups allowing C
2
 
substitutions to be tuned for improved water solubility and other functions.
1
 The focus of this 
experiment was the substitution of secondary alcohol groups onto the C
2
 position of 1, as the 
synthesis of these types of compounds had not previously been attempted. In addition to the anti-
tumor activity, the synthesis and characterization was of interest because the results may give 
insight into improving the methodology involved with purifying this class of imidazolium salts. 
 
 
 
 
Fig. 2: General structure of an imidazolium salt with carbon atoms labeled numerically. 
4 
Methods 
 Chemicals and Instrumentation: The chemicals used in this experiment were obtained 
from: Fisher Scientific (sodium bromide, acetonitrile, acetic acid), Sigma-Aldrich (acetone, 
methanol, ethanol, mixed hexanes, chloroform, dichloromethane), Fluka Analytical 
(fluorescence indicator green 254 nm), Alfa Aesar (hydrobromic acid, N,N-
diisopropylethylamine, hexanal 98 %, 4-hydroxybenzaldehyde 98 %), Cambridge Isotope 
Laboratories Inc. (DMSO-δ6), Acros Organics (imidazole, valeraldehyde 97 %), EMD Millipore 
Chemicals (sodium bicarbonate, diethyl ether, heptane, N,N-dimethylformamide, toluene), and 
Waterstone Tech LLC (2-(bromomethyl)naphthalene). Butanal was obtained from the organic 
chemistry lab at the University of Akron and kept in a refrigerator. Instruments used include: 
Apex Duo XRD (x-ray crystallography), Electrothermal Mel-Temp (melting point), Mettler 
AE200 (analytical balance), Fisher Scientific Analog Vortex Mixer (sample mixing), Corning 
Stirring Hot Plate (oil bath heating), Schlenck vacuum glassware (compound purification by 
vacuum), Büchi Heating Bath B-490 (rotary evaporation bath), Büchi Rotavapor RE111 (rotary 
evaporation), and Isotemp Fischer Scientific Refrigerator Freezer (recrystallization and storage). 
NMR spectroscopy was performed on a Varian 300, 400, and 500 MHz NMR with all spectra 
referenced to 2.50 ppm (
1
H) and 39.5 ppm (
13
C) corresponding to the deuterated solvent DMSO-
δ6. A Trevigen MTT Cell Proliferation Assay kit was used by Michael DeBord to conduct MTT 
assays. The reagent compounds for the synthesis of 2-5 (Scheme 2) was provided by Dr. Wiley 
Youngs’ lab at the University of Akron. Mass spectrometry was performed by Dr. Wesdemiotis’ 
analytical chemistry group at the University of Akron. All reactions were conducted in aerobic 
conditions and no further purification was used on any reagents or solvents. The synthesis of 
5 
compounds 2-5 were modified from procedures for substituting alcohols onto the C
2
 position of 
an imidazolium salt provided in the literature.
1,11
 
 MTT Assay Protocol: All MTT assays were performed by Michael DeBord. The following 
standards are provided in the literature.
1
 Human non-small cell lung cancer lines NCI-A549, 
NCI-H460, HCC827, and NCI-H1975 were incubated for 24 h with 5000 – 7000 cells per well 
(depending on cell line) in a 96-well plate. Stock solutions of compound 3 and cisplatin were 
each dissolved in a 1 % DMSO/H2O solution and further diluted to 1, 4, 16, and 32 μM in cell 
medium (DMEM, maintained at 37 degrees and 5% CO2). Six replicates at each concentration 
were added to the plates and incubated for 72 h. A solution of 10 μL MTT reagent in PBS was 
added to each well and incubated for 3 - 4 h (depending on cell line) followed by removal of the 
cell medium and the addition of 100 μL DMSO.1 The plates were then read with a Biotek Epoch 
plate reader at 540 nm.
1
 
 Synthesis of 1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide (1): The synthesis of 
compound 1 was modified from a procedure provided in the literature.
1
 Imidazole (0.540 g, 7.93 
mmol) and potassium hydroxide (0.670 g, 11.9 mmol) were stirred in 10 mL acetonitrile and 
refluxed for 60 min. This was followed by the slow addition of 2-(bromomethyl)naphthalene 
(1.78 g, 8.05 mmol) with continued reflux at 82 ⁰C for 60 min. The solution was filtered to 
remove the yellow/red precipitate (1.06 g). A second equivalent of 2-(bromomethyl)naphthalene 
(1.78 g, 8.05 mmol) and 10 mL acetonitrile was added to the remaining solution and refluxed 
overnight. The volatile components were removed by rotary evaporation and the remaining oil 
precipitated with acetone. The product was then ground to a fine powder with mortar and pestle 
and stirred in acetone for 24 h. 
1
H NMR (300 MHz, DMSO-δ6): δ = 9.50 (1H, s, NCHN), 8.01 – 
7.91 (12H, m, Ar), 7.59 – 7.53 (6H, m, Ar), 5.62 (4H, s, CH2), 2.08 (CH3CN, impurity). 
6 
 Synthesis of 2-(1-hydroxybutyl)-1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide 
(2): Compound 1 (0.501 g, 1.17 mmol) was dissolved in 1.5 mL DMF and 3.0 mL (17.4 mmol) 
N,N-diisopropylethylamine (DIPEA). Butyraldehyde (0.400 mL, 4.44 mmol) was subsequently 
added and the solution heated and stirred in a pressure vessel at 80 ⁰C overnight. The orange/red 
liquid was diluted with 60 mL dichloromethane and extracted twice with saturated brine (sodium 
bromide in water) and a 1:10 (v/v) hydrobromic acid in water solution. Volatiles were then 
removed with rotary evaporation yielding a red/brown oil which was stirred and precipitated in 
diethyl ether overnight. The product was then filtered yielding a brown solid. Crude product 
yield: 0.462 g, 79 % yield. 
1
H NMR (300 MHz, DMSO-δ6) did not confirm synthesis.  
 Synthesis of 2-(1-hydroxypentyl)-1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide 
(3): Compound 1 (0.500 g, 1.16 mmol) was dissolved in 1.5 mL (8.70 mmol) DIPEA and 3.0 mL 
DMF. Valeraldehyde (0.500 mL, 4.70 mmol) was added and the solution heated and stirred at 80 
⁰C overnight. The orange/red liquid was diluted with 60 mL dichloromethane and extracted 
twice with a 1:10 (v/v) hydrobromic acid in water and saturated brine solution (sodium bromide 
in water). The volatile components were then removed with rotary evaporation generating a 
red/orange oil which was stirred and precipitated with diethyl ether overnight. A silica gel 
column was prepared using a green fluorescence indicator and 3:1 (v/v) dichloromethane and 
methanol solution allowing the product to be separated into five fractions using flash column 
chromatography. The first two fractions were combined and reduced using rotary evaporation 
and precipitated with diethyl ether. The product was then placed under vacuum using a Schlenk 
line for 24 h followed by recrystallization in cold acetonitrile and placed under vacuum 
overnight. The crystals were ground to a fine powder and placed under vacuum overnight. The 
flask containing the crystals was heated to 80 °C using an oil bath. Obtained 0.110 g (18 % 
7 
yield) of a fine white powder. MP: 174 – 176 ⁰C. MS: m/z = 435.6 (theoretical for M+ = 435.2). 
1
H NMR (500 MHz, DMSO-δ6): δ = 9.50 (IC23H, impurity), 7.99 – 7.90 (10H, m, Ar), 7.56 – 
7.48 (6H, m, Ar), 6.60 (1H, d, OH, J = 3.90 Hz), 5.82 (4H, q, CH2, J = 5.81 Hz), 5.65 (IC23H, 
impurity), 5.34 (1H, quin, CH, J = 9.2 Hz), 2.07 (CH3CN, impurity), 1.58 (2H, d, CH2, J = 9.8 
Hz), 1.19 – 1.07 (2H, m, CH2), 0.80 (2H, m, CH2), 0.41 (3H, m, CH3). 
13
C{
1
H} NMR (125 MHz, 
DMSO-δ6): δ = 147.6 (NCN), 132.6 (Ar), 132.2 (Ar), 128.7 (Ar), 127.7 (Ar), 127.6 (Ar), 126.8 
(Ar), 126.6 (Ar), 125.1 (Ar), 123.1 (Ar), 64.0 (COH), 51.4 (CH2), 34.0 (CH2), 27.0 (CH2), 21.3 
(CH2), 13.1 (CH3).  
 Synthesis of 2-(hydroxyl(4-hydroxyphenyl)methyl)-1,3-bis(naphthalen-2-ylmethyl)-
imidazolium bromide (4): Compound 1 (0.501 g, 1.17 mmol) was dissolved in 1.5 mL (8.70 
mmol) DIPEA and 3.0 mL DMF followed by the addition of 4-hydroxybenzaldehyde (0.152 g, 
1.25 mmol). The solution was heated at 80 ⁰C overnight then diluted with 60 mL 
dichloromethane. The solution was then extracted twice with 1:10 (v/v) hydrobromic acid in 
water and saturated brine (sodium bromide in water). Volatiles were removed with rotary 
evaporation giving an oil which was then stirred and precipitated with diethyl ether. The product 
was filtered and washed with acetone to remove colored impurities. 
1
H NMR (300 MHz, DMSO-
δ6) did not confirm synthesis.  
 Synthesis of 2-(1-hydroxyhexyl)-1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide 
(5): Compound 1 (0.501 g, 1.17 mmol) was dissolved in 1.5 mL DMF and 3.0 mL (17.4 mmol) 
DIPEA followed by the addition of hexanal (0.500 mL, 4.07 mmol). The solution was heated at 
80 ⁰C overnight then diluted with 60 mL dichloromethane. The solution was then extracted twice 
with 1:10 (v/v) hydrobromic acid in water and saturated brine (sodium bromide in water). The 
volatile components were removed by rotary evaporation and the remaining oil precipitated in 
8 
diethyl ether and filtered giving an orange/white powder. The product was then ground and 
placed under vacuum. A fluorescent silica gel column was prepared using a green fluorescence 
indicator and 9:1 (v/v) dichloromethane and methanol solution with the addition of 20 mL acetic 
acid. The product was dissolved in ~ 3 mL of the solvent system resulting in 10 fractions after 
flash column chromatography. Fractions 1 – 4 were combined and the volatile components 
removed by rotary evaporation giving an oil. The oil was stirred and precipitated with diethyl 
ether, filtered, and placed under vacuum for ~ 12 h. Obtained 0.271 g (44 % yield) of a fine 
white powder. MP: 144 – 146 ⁰C. MS: m/z = 449.3 (theoretical for M+ = 449.3). 1H NMR (500 
MHz, DMSO-δ6): δ = 9.49 (IC23H, impurity), 7.99 – 7.86 (11H, m, Ar), 7.57-7.46 (7H, m, Ar), 
6.57 (1H, s, OH), 5.78 (4H, m, CH2), 5.61 (IC23H), 5.30 (1H, s, CH), 1.55 (2H, d, CH2, J = 10.3 
Hz), 1.20 (2H, comp, CH2), 1.05 (2H, comp, CH2), 0.86 – 0.63 (6H, comp, CH2), 0.53 (3H, t, 
CH3, J = 7.1 Hz). 13C{
1
H} NMR (125 MHz, DMSO-δ6): δ = 147.5 (NCN), 132.6 (Ar), 132.3 
(Ar), 128.7 (Ar), 127.8 (Ar), 127.6 (Ar), 126.7 (Ar), 125.0 (Ar), 123.2 (Ar), 64.1 (COH), 51.4 
(CH2), 34.4 (CH2), 30.4 (CH2), 24.5 (CH2), 21.5 (CH2), 13.5 (CH3). 
Results and Discussion 
 Synthesis and Characterization: Compound 1 served as the foundation for the synthesis of 
novel compounds with secondary alcohol substituents at the C
2
 position. Compound 1 was 
synthesized using imidazole and two equivalents of 2-(bromomethyl)naphthalene in acetonitrile 
and potassium hydroxide at 82 ⁰C (Scheme 1). The yellow/red precipitate filtered after the first 
addition of 2-(bromomethyl)naphthalene was most likely potassium bromide which remained 
colored due to an insufficient washing with acetonitrile. A 
1
H NMR (300 MHz, DMSO-δ6) 
spectrum was then obtained (Fig. 4) to confirm the presence of the intermediate monosubstituted 
imidazole (Scheme 1). Resonance at 9.47 ppm and in the 7.96 – 7.76 ppm region indicated the 
9 
presence of a proton at the C
2
 position and aromatic protons, respectively. Resonance at 5.60 
ppm indicated presence of the methylene protons corresponding to the “bridge” between the 
imidazole ring and naphthalene. This chemical shift was also evident on the spectrum for the 
final product (Fig. 3, δ = 5.62). Obtaining this intermediate spectrum was useful for verifying the 
first step of the reaction had occurred.  Precipitation and stirring in acetone for 24 h gave a nearly 
pure product confirmed by 
1
H NMR (Fig. 3). Resonance at 2.08 ppm was most likely an 
acetonitrile impurity which could be removed if the compound were placed under vacuum. Due 
to acetonitrile being used in the future synthesis of 2-5, no additional purification was necessary 
for this material. Resonance at 9.50 ppm (Fig. 3) corresponded to the proton at the C
2 
position of 
1, a key structural feature for identifying the compound, shifted downfield due to the nearby 
nitrogen atoms in the imidazole ring.  
 The synthesis of 2-5 (Scheme 2) followed the same general procedure for reaction of various 
aldehydes with 1 to give secondary alcohol substituents at the C
2
 position. This general 
procedure began by combining the imidazolium salt reagent 1 with the base DIPEA before 
addition of the aldehyde and heating to 80 °C. A molar ratio of approximately 2:1 DIPEA to 
aldehyde was used in the synthesis of 3 and 4 and 4:1 in the synthesis of 2 and 5. The base’s 
function was to deprotonate 1 at the C
2
 position enabling the aldehyde substitution. Compound 2 
was unable to be synthesized to a substantial degree due to oxidation of the reagent, butanal. The 
downfield shift of the carboxylic acid proton a1 (11.98 ppm) from the aldehyde proton a (9.66 
ppm) suggests partial oxidation occurred. The reduced amount of available butanal may have 
prevented the reaction from occurring. Fig. 5 does not display resonance at 6.50 ppm which is 
expected for the intended hydroxyl proton, nor does it display a sufficient number of chemical 
shifts in the alkyl region for the 1-hydroxybutyl chain. Due to some aldehyde remaining present 
10 
in the oxidized reagent, it was expected that some of the intended product was still formed 
despite poor yield and lack of substantial NMR evidence in Fig. 5.  
 The synthesis of 3 and 5 proved challenging due to difficulties in removing the starting 
material. Ultimately, IC23H impurities remained in small amounts based on 
1
H NMR (Fig. 7, 9). 
After extraction and rotary evaporation of 3, a 
1
H NMR was obtained (Fig. 13) showing evidence 
of 1 at chemical shifts 9.46 ppm and 5.61 ppm. Residual diethyl ether from precipitation was 
apparently due to resonance at 3.63 ppm.
12
 Flash column chromatography was selected in an 
attempt to separate the residual starting material from the product due to the expected differences 
in polarities between the compounds. Thin-layer chromatography (TLC) was used to determine 
the optimum solvent combination and ratio of solvents for the column. A 3:1 (v/v) mixture of 
dichloromethane to methanol provided the greatest amount of separation. For the purposes of 
TLC, acetic acid (6 drops) was added to decrease the amount of “smearing” of the spots, but was 
not added to the column. Acetic acid’s high polarity and ability to decrease fraction size may 
have enabled better separation. It was noted that 3 traveled further on the TLC plates and eluted 
first from the column compared to 1. These results were interesting, as the hydroxyl group on 3 
was expected to have increased polarity compared to 1 thereby decreasing its Rf value. However, 
the naphthalene substituents and imidazole ring may have created a great electron delocalization 
effect negating any substantial polarity differences leading to this result. Fractions containing no 
starting material were combined, reduced by rotary evaporation, and precipitated with diethyl 
ether. The remaining solids were then placed under vacuum for attempted removal of residual 
diethyl ether. Based on 
1
H NMR (Fig. 14), the column was successful in removing the starting 
material but showed evidence of diethyl ether impurities at 3.38 ppm and 3.16 ppm. 
Recrystallizing in acetonitrile, followed by vacuum, grinding to a fine powder, and repeated 
11 
vacuum with heat gave the final product with an 18 % yield. The yield could possibly be 
improved by increasing the amount of base (DIPEA) used (such as in the synthesis of 5). Mass 
spectrometry data (Appendix 2, Chart 1) supported the synthesis of 3 as the experimental mass 
(435.6 g/mol) was near the theoretical M
+ 
of 435.2 g/mol. Significant product loss occurred 
during column chromatography and purification. A more highly concentrated sample analyzed 
with a 500 MHz 
1
H NMR (Fig. 7) showed evidence of residual IC23H resonance at 9.60 ppm 
and 5.65 ppm, in addition to acetonitrile at 2.07 ppm. The 
13
C{
1
H} (125 MHz, DMSO-δ6) 
spectrum suggested the presence of the pentyl chain due to the 4 unique upfield shifts (Fig. 8). It 
is clear that further purification techniques were needed to remove the starting material. The 
nature of these substituted imidazolium salts may be such that there is not a significant difference 
in polarity or solubility between 1 and 3, or that better separation conditions are needed. A longer 
column or different technique such as HPLC may improve the results. Crystal trials were 
attempted for mixed solvents (acetone/water, methanol/water) and single solvents (ethanol, 
acetonitrile, methanol) giving visible crystals for ethanol and acetone/water; however, none of 
these crystals were suitable to obtain high quality X-ray crystallographic data. 
 Compound 5 followed a similar synthetic and purification methodology as 3 but did not 
require recrystallization in acetonitrile after elution from the silica gel column and resulted in a 
nearly 2.5 times greater yield (44 %). Mass spectrometry data (Appendix 2, Chart 3) supported 
the synthesis of 5 as the experimental mass (449.3 g/mol) matched the theoretical M
+ 
of 435.2 
g/mol. Unlike 3, this compound was synthesized using 17.4 mmol of the base DIPEA compared 
to 8.70 mmol and was placed under vacuum before flash column chromatography. A slightly 
different solvent system for column chromatography was used (9:1 (v/v) dichloromethane and 
methanol) but with the addition of 20 mL acetic acid. Visibly, the column did not appear to give 
12 
significant separation as the effluent elongated across the entire length of the column. Despite 
this, 10 fractions were obtained with the first 4 showing no evidence of 1 by TLC. These 
fractions were combined, reduced by rotary evaporation, and precipitated to give a white powder 
which was then placed under vacuum. A 
1
H NMR (300 MHz) was obtained (Fig. 15) giving no 
evidence of IC23H impurities. However, a 
1
H NMR (500 MHz, DMSO-δ6) (Fig. 9) showed 
resonance at 9.49 ppm and 5.61 ppm corresponding to 1, but did not show evidence of 
acetonitrile as was apparent in Fig. 7 for 3. The 
13
C{
1
H} (125 MHz, DMSO-δ6) spectrum 
suggested the presence of the hexyl chain due to the 5 unique upfield shifts (Fig. 10). Crystal 
trials were attempted using mixed-solvents (ethanol/water, methanol/water, acetone/water) and 
single solvents (acetone, ethanol). Crystals grew for methanol/water, acetone, and ethanol but 
again, none were suitable for obtaining high quality data. The chiral center at the carbon to which 
the hydroxyl group is bonded in both 5 and 3 (Scheme 2) may have led to a racemic product 
containing both stereoisomers increasing the complexity of the crystal structure.  
 The successfully synthesized compounds 3 and 5 demonstrated unique NMR features. Both 
compounds exhibit chirality (Scheme 2) at the carbon to which the hydroxyl group is attached. 
The methylene groups bridging the nitrogen of the imidazole ring to the naphthalene substituent 
on both imidazolium salts resonate as apparent quartets at chemical shifts 5.82 ppm (3, Fig. 16) 
and 5.78 ppm (5, Fig. 17). Due to the chirality of both compounds, each methylene group will 
exist in a different conformation resulting from a lack of symmetry. The apparent quartet could 
be considered “facing doublets” as each methylene group splits as an independent doublet with 
one equivalent proton. Furthermore, on the 
1
H NMR (500 MHz, DMSO-δ6) for 3 (Fig. 7), the 
shift corresponding to the hydroxyl proton (δ = 6.60) is a doublet (Fig. 18), which supports the 
13 
chirality of the structure due to slightly different splitting patterns for each isomer; however, this 
doublet is not apparent in 5 (Fig. 9).  
Compound 4 was unique in that it was the only attempted synthesis with a non-alkyl 
aldehyde but was unable to be synthesized most likely due to lack of reaction of 1 with 4-
hydroxybenzaldehyde. The 
1
H NMR spectrum for 4 is similar to that of 1 (Fig. 11) and the 
spectrum for 4-hydroxybenzaldehyde (Fig. 12) does not show evidence of oxidation to 
carboxylic acid. If no reaction occurred, the aldehyde would have been removed during 
extraction giving the original imidazolium salt that was observed by NMR. The 4-
hydroxybenzaldehyde reagent (Fig. 12) has a singlet at chemical shift 10.60 ppm corresponding 
to the hydroxyl proton c. The chemically equivalent protons at position a are split by b, which 
are split by a. This splitting by neighboring equivalent protons resulted in the doublets resonating 
at chemical shifts 6.91 – 6.94 ppm and 7.74 – 7.77 ppm, respectively. The singlet resonating at 
9.78 ppm was shifted downfield by the nearby carbonyl group. The difference in structure and 
increased molecular weight for this reagent compared to the alkyl aldehydes in the synthesis of 2, 
3, and 5 may have prevented reaction. A 1:1 molar ratio of aldehyde to 1 was also used instead 
of the typical ~ 4:1 ratio which was successful in the synthesis of 3 and 5. The 4-
hydroxybenzaldehyde structure contains a benzene ring which acts as an electron donating 
group, creating an electron delocalization effect that increases the electrophilicity of the carbonyl 
carbon. Furthermore, the bulk of the benzene ring may have created significant steric hindrance. 
Increasing the molar equivalent of the base DIPEA may have also helped increase reactivity by 
ensuring the starting material was deprotonated for substitution.  
  
14 
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Fig. 3: 
1
H NMR (300 MHz, DMSO-δ6) for compound 1. 
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Fig. 4: 
1
H NMR (300 MHz, DMSO-δ6) of intermediate monosubstituted imidazolium salt, 1-(naphthalen-
2-ylmethyl)-imidazole in the synthesis of 1. 
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Fig. 5: 
1
H NMR (300 MHz, DMSO-δ6) for the synthesis of 2.  
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Fig. 6: 
1
H NMR (300 MHz, DMSO-δ6) for butanal in the synthesis of 2 displaying evidence of oxidation 
at δ = 11.98. 
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Fig. 7: 
1
H NMR (500 MHz, DMSO-δ6) for compound 3. 
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Fig. 8: 
13
C{
1
H} NMR (125 MHz, DMSO-δ6) for compound 3. 
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Fig. 8b: Zoomed aromatic region of 
13
C{
1
H} NMR (125 MHz, DMSO-δ6) for 3 (Ref. Fig. 8).  
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Fig. 9: 
1
H NMR (500 MHz, DMSO-δ6) for compound 5. 
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Fig. 9b: Zoomed alkyl region of 
1
H NMR (500 MHz, DMSO-δ6) for 5 (Ref. Fig. 9). 
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Fig. 10: 
13
C{
1
H} NMR (125 MHz, DMSO-δ6) for compound 5. 
19 
136 134 132 130 128 126 124 122 120 118
Chemical Shift (ppm)
1
2
3
.2
1
2
5
.0
1
2
6
.6
1
2
6
.7
1
2
6
.7
1
2
7
.6
1
2
7
.8
1
2
8
.7
1
3
2
.31
3
2
.6
s
b - k
 
Fig. 10b: Zoomed aromatic region of 
13
C{
1
H} NMR (125 MHz, DMSO-δ6) for 5 (Ref. Fig. 10).  
 
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
9
.4
9
8
.0
1
7
.9
7 7
.9
1
7
.9
1
7
.5
9
7
.5
6
7
.5
3
5
.6
1
3
.3
4
2
.5
0b
a
c
w ater
DMSO
 
Fig. 11: 
1
H NMR (300 MHz, DMSO-δ6) for the synthesis of 4. Resonance suggests only 1 present.  
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Fig. 12: 
1
H NMR (300 MHz, DMSO-δ6) for 4-hydroxybenzaldehyde in the synthesis of 4. 
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Fig. 13: 
1
H NMR (400 MHz, DMSO-δ6) for 3 after initial precipitation of product.  
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Fig. 14: 
1
H NMR (300 MHz, DMSO-δ6) for 3 after column chromatography and vacuum.  
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Fig. 15: 
1
H NMR (300 MHz, DMSO-δ6) for 5 after column chromatography and vacuum to remove 
residual diethyl ether.  
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Fig. 16: 
1
H NMR (500 MHz, DMSO-δ6) for downfield region of compound 3 (Ref. Fig. 7). 
8.0 7.5 7.0 6.5 6.0
Chemical Shift (ppm)
4.451.006.1910.34
5
.7
4
5
.7
7
5
.7
9
5
.8
2
6
.5
7
7
.4
6
7
.4
8
7
.5
6
7
.5
7
7
.5
77
.8
6
7
.9
1
7
.9
2
7
.9
3
7
.9
8
7
.9
9
a
b
c
 
Fig. 17: 
1
H NMR (500 MHz, DMSO-δ6) for downfield region of compound 5 (Ref. Fig. 9). 
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Fig. 18: Zoomed region of 
1
H NMR (500 MHz, DMSO-δ6) for 3 (Ref. Fig. 7). 
 
 
Scheme 1: Synthesis of compound 1; 1,3-bis(naphthalen-2-ylmethyl)-imidazolium bromide (IC23H). 
 
 
Scheme 2: Synthesis and general structures of compounds 2-5 showing chirality (*).  
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Anti-Tumor Activity: An MTT assay was used to determine the in vitro activity of 3 against 
NSCLC lines NCI-A549, NCI-H460, HCC827, and NCI-H1975. For each cell line, 3 and 
cisplatin were dissolved in 1 % DMSO/H2O solutions and diluted to six replicates of 1, 4, 16, 
and 32 μM. A plot of cell growth (in percent) against concentration was generated for each cell 
line (Charts 1-4). The IC50 value was established to standardize comparisons (Table 1) between 
each compound. For a more thorough comparison, the results from a similarly conducted MTT 
assay of 1 obtained in the literature were included in Table 1.
1
 Lower IC50 values were 
considered optimal as they indicated greater activity at lower concentrations, therefore increasing 
effectiveness. Cisplatin had a lower IC50 value than 1 and 3 for each cell line except NCI-H1975, 
and compound 3 demonstrated greater activity against HCC827 and NCI-H1975 than 1. The 
overall results suggested compounds 1, 3, and cisplatin have similar anti-tumor activity against 
select NSCLC cell lines. This evidence may allow for the future synthesis of novel imidazolium 
salts with functional groups at the C
2
 position that improve other physical properties, as the 
secondary alcohol substituent did not substantially affect activity compared to 1.  
IC50 (μM) NCI-A549 NCI-H460 HCC827 NCI-H1975 
Compound 3 9 7 5 3 
Cisplatin 5 3 3 8 
Compound 1
 
n/a 4 9 6 
 
Table 1: Concentration of compound 3, 1, and cisplatin at 50 % cell growth for select NSCLC cell lines. 
Values for 1 were obtained from the literature and were not tested in this experiment.
1
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Chart 1: MTT assay results for compound 3 and cisplatin against NSCLC cell line NCI-A549 in-vitro. 
This chart was modified from MTT data obtained by Michael DeBord.  
 
 
Chart 2: MTT assay results for compound 3 and cisplatin against NSCLC cell line NCI-H460 in-vitro. 
This chart was modified from MTT data obtained by Michael DeBord. 
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Chart 3: MTT assay results for compound 3 and cisplatin against NSCLC cell line HCC827 in-vitro. This 
chart was modified from MTT data obtained by Michael DeBord. 
 
 
Chart 4: MTT assay results for compound 3 and cisplatin against NSCLC cell line NCI-H1975 in-vitro. 
This chart was modified from MTT data obtained by Michael DeBord. 
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Conclusion 
 Several novel imidazolium salts were synthesized for the study of in vitro activity against 
NSCLC lines NCI-A549, NCI-H460, HCC827, and NCI-H1975 compared to cisplatin. Various 
aldehydes were combined with 1 to synthesize imidazolium salts with secondary alcohol groups 
at the C
2
 position. Compounds 3 and 5 were successfully synthesized and characterized in yields 
of 18 % and 44 %, respectively. Compounds 2 and 5 showed no evidence of synthesis as the 
aldehyde starting materials were oxidized or did not react. Further work should be done to purify 
compounds 3 and 5 due to the presence of residual solvent and compound 1 evident in the 
1
H 
NMR spectra. An MTT assay was used to test the anti-tumor activity of 3 and cisplatin for each 
cell line in concentrations of 1, 4, 16, and 32 μM giving comparable IC50 values (Table 1). The 
IC50 values for 1 were obtained from the literature and showed similar results. Compound 3 has 
the lowest IC50 value against the H1975 cell line compared to either 1 or cisplatin. Although 
cisplatin had a lower IC50 value for the other cell lines, the similarity in results suggests that 3 
may be effective in treating non-small cell lung cancer, with the addition of a secondary alcohol 
group not significantly affecting the activity compared to 1. If compounds 3 and 5 can be 
completely purified and 2 synthesized, insight into the effects of increasing carbon chain length 
may be possible with an additional MTT assay. X-ray crystallography of 3 and 5 gave poor 
results which were not included. Further purification of these compounds may lead to more 
accurate anti-tumor activity data and future characterization by x-ray crystallography if optimum 
crystal growth conditions are attained. These results are important because they suggest that C
2
 
substituents on 1 do not significantly change efficacy against NSCLC. With this in mind, 
continuing to increase the library of novel compounds may be helpful in understanding the 
28 
possible role of imidazolium salts as chemotherapeutic agents. Different C
2
 functional groups 
can be selected to change other physical properties that may be clinically relevant.   
29 
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